TARBP2

Across TCGA pan-cancer cohorts, TARBP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TARBP2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TARBP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TARBP2 expression acts as an unfavorable survival marker.

HNSC, BLCA, and KICH are the cancer types where TARBP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.013	0.743	<.001	40	view →
BLCA	OS	Median	All	0.244	0.721	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TARBP2–HNSC (OS)

Open the HNSC breakdown →